Predicted Relatlimab Exposures at 160 mg Q4W (Relatlimab Plus Nivolumab) by Body Weight Quartiles in Adults
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: